Tarloxotinib

DB14944InvestigationalSmall molecule

Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).

Chemical structure of Tarloxotinib
Formula / weight
C24H24BrClN9O3 · 601.87 g/mol (avg)

Resolves to

Compound
UNIIH8768UL06VCAS1636938-13-0
Structure
InChIKeyMUJMYVFVAWFUJL-SNAWJCMRSA-OSMILESCN1C=NC(=C1C[N+](C)(C)C\C=C\C(=O)NC1=NC=C2N=CN=C(NC3=CC(Br)=C(Cl)C=C3)C2=C1)[N+]([O-])=O
Targets
P00533EGFRP04626ERBB2

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tarloxotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In